Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy

被引:0
|
作者
Hartrampf, Philipp E. [1 ]
Mihatsch, Patrick W. [2 ]
Seitz, Anna Katharina [3 ]
Solnes, Lilja B. [4 ]
Rowe, Steven P. [4 ]
Pomper, Martin G. [4 ]
Kuebler, Hubert [3 ]
Bley, Thorsten A. [2 ]
Buck, Andreas K. [1 ]
Werner, Rudolf A. [1 ,4 ]
机构
[1] Univ Hosp Wurzburg, Dept Nucl Med, Wurzburg, Germany
[2] Univ Hosp Wurzburg, Dept Diagnost & Intervent Radiol, Wurzburg, Germany
[3] Univ Hosp Wurzburg, Dept Urol & Paediat Urol, Wurzburg, Germany
[4] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD USA
关键词
PSMA; prostate cancer; radioligand therapy; overall survival; body composition; ANDROGEN-DEPRIVATION THERAPY; CLINICAL-OUTCOMES; OPEN-LABEL; MEN; FAT; CHEMOTHERAPY; MITOXANTRONE; CABAZITAXEL; ABIRATERONE; PREDNISONE;
D O I
10.2967/jnumed.122.265379
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In patients with prostate cancer scheduled for systemic treatment, being overweight is linked to prolonged overall survival (OS), whereas sarcopenia is associated with shorter OS. We investigated fat-related and body composition parameters in patients undergoing prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) to assess their predictive value for OS. Methods: Body mass index (BMI, in kg/m(2)) and CT-derived body composition parameters (total, subcutaneous, visceral fat area, and psoas muscle area at the L3-L4 level) were determined for 171 patients scheduled for PSMA-directed RLT. After normalization for stature, the psoas muscle index was used to define sarcopenia. Outcome analysis was performed using Kaplan-Meier curves and Cox regression including fat-related and other clinical parameters (Gleason score, C-reactive protein [CRP], lactate dehydrogenase [LDH], hemoglobin, and prostate-specific antigen levels). The Harrell C-index was used for goodness-of-fit analysis. Results: Sixty-five patients (38%) had sarcopenia, and 98 patients (57.3%) had increased BMI. Relative to the 8-mo OS in normal-weight men (BMI < 25), overweight men (25 = BMI > 30) and obese men (BMI =30) achieved a longer OS of 14 mo (hazard ratio [HR], 0.63; 95% CI, 0.40-0.99; P = 0.03) and 13 mo (HR, 0.47; 95% CI, 0.29-0.77; P = 0.004), respectively. Sarcopenia showed no impact on OS (11 vs. 12 mo; HR, 1.4; 95% CI, 0.91-2.1; P = 0.09). Most of the body composition parameters were tightly linked to OS on univari-able analyses, with the highest C-index for BMI. In multivariable analy-sis, a higher BMI (HR, 0.91; 95% CI, 0.86-0.97; P = 0.006), lower CRP (HR, 1.09; 95% CI, 1.03-1.14; P < 0.001), lower LDH (HR, 1.08; 95% CI, 1.03-1.14; P < 0.001), and longer interval between initial diagnosis and RLT (HR, 0.95; 95% CI, 0.91-0.99; P = 0.02) were significant pre-dictors of OS. Conclusion: Increased fat reserves assessed by BMI, CRP, LDH, and interval between initial diagnosis and RLT, but not CT-derived body composition parameters, were relevant predictors for OS. As BMI can be altered, future research should investigate whether a high-calorie diet before or during PSMA RLT may improve OS.
引用
收藏
页码:1272 / 1278
页数:7
相关论文
共 50 条
  • [31] Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening
    Hutterer, Georg
    Perrotte, Paul
    Gallina, Andrea
    Walz, Jochen
    Jeldres, Claudio
    Traumann, Miriam
    Suardi, Nazareno
    Saad, Fred
    Benard, Francois
    Valiquette, Luc
    McCormack, Michael
    Graefen, Markus
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (07) : 1180 - 1187
  • [32] Body mass index does not alter prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening
    Hutterer, Georg C.
    Perrotte, Paul
    Gallina, Andrea
    Walz, Jochen
    Jeldres, Claudio
    Traumann, Miriam
    Suardi, Nazareno
    Benard, Francois
    Valiquette, Luc
    Mc Cormack, Michael
    Graefen, Markus
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 628 - 629
  • [33] Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
    Calderoni, Letizia
    Maietti, Elisa
    Farolfi, Andrea
    Mei, Riccardo
    Louie, Karly S.
    Groaning, Michael
    Fanti, Stefano
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (06) : 910 - 917
  • [34] Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy
    Halabi, Susan
    Armstrong, Andrew J.
    Sartor, Oliver
    de Bono, Johann
    Kaplan, Ellen
    Lin, Chen-Yen
    Solomon, Nicole C.
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) : 3944 - +
  • [35] The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review
    Martin, Felicity C.
    Dorff, Tanya B.
    Tran, Ben
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [36] Prostate-specific antigen kinetics in patients with bone metastases from castration-resistant prostate cancer receiving zoledronic acid therapy
    Saad, F.
    Perez, J.
    Segal, S.
    Eastham, J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E918 - U930
  • [37] IMPROVED SURVIVAL PROSPECTS FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Kirby, Roger S.
    Fitzpatrick, John M.
    BJU INTERNATIONAL, 2011, 107 (05) : 697 - 700
  • [38] EVALUATION OF PROSTATE-SPECIFIC ANTIGEN KINETICS DURING ZOLEDRONIC ACID THERAPY FOR BONE METASTASES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Saad, Fred
    Perez, Jose
    Cook, Richard
    Segal, Scott
    JOURNAL OF UROLOGY, 2011, 185 (04): : E288 - E288
  • [39] Predictors of overall survival in patients with metastatic castration-resistant prostate cancer
    Markova, A. S.
    Polikarpova, S. B.
    Kamolov, B. Sh.
    Gridneva, Ya. V.
    Kalinin, S. A.
    Peters, M. V.
    Matveev, V. B.
    ONKOUROLOGIYA, 2015, 11 (02): : 77 - 84
  • [40] Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
    Nagaya, Naoya
    Nagata, Masayoshi
    Lu, Yan
    Kanayama, Mayuko
    Hou, Qi
    Hotta, Zen-u
    China, Toshiyuki
    Kitamura, Kosuke
    Matsushita, Kazuhito
    Isotani, Shuji
    Muto, Satoru
    Sakamoto, Yoshiro
    Horie, Shigeo
    PLOS ONE, 2020, 15 (01):